


COMPANY OVERVIEW

A genetics company creating product platforms that encompass gene therapy, cancer immunotherapy, and gene editing. Their goal is a one-time treatment option for patients with severe genetic and rare diseases, and cancer.

They are a publicly held company with a valuation of \$4.5 billion.

In early 2015, the Food and Drug Administration gave the designation of “breakthrough therapy” to Bluebird Bio’s LentiGlobin BB305, an experimental treatment for beta thalassemia, a rare blood disorder. This treatment is currently being evaluated in four clinical studies.



Patinformatics, LLC®
Patent Landscape Reports


ANALYSIS:

Bluebird Bio’s portfolio is concentrated solely in the Chemistry sector and they have shown steady growth since 2012.

Their focus is currently in four fields: Biomolecule Drug Preparations, Genetic Engineering, Biomolecule Discovery, and Culturing Biomolecules. In 2017 patent families in Biomolecule drug preparations, and Genetic Engineering are projected to increase while those in Biomolecule discovery are expected to decrease.

More of the top inventors have left than are currently with the firm. This seems to show some instability; however, the top two most prolific inventors are still with the company.

Over 80% of their portfolio has been grown organically while the remaining 20% is made up of patent families from MIT, Five Prime, ViorMed and Eureka Ther.




PORTFOLIO DEVELOPMENT




■ Bluebird Bio ■ MIT ■ Five Prime ■ ViorMed ■ Eureka Ther

PATENT FAMILIES BY SECTOR




TOP INVENTORS BY CURRENT AFFILIATION



■ With Company ■ Not with Company

PATENT FAMILIES BY FIELD



Patinformatics, LLC®
Patent Landscape Reports